Biohaven strikes $795M deal for commercial partner in epilepsy

Biohaven has found a commercial partner for its late-stage epilepsy drug. South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel platform, including its lead candidate ...